163 related articles for article (PubMed ID: 6299046)
41. [Long-term treatment of chronic heart failure by an inhibitor of angiotensin converting enzyme].
Komajda M; Eugène M; Evans J; Laurenceau JL; Hubermann JP; Thomas D; Drobinski G; Leprince JL; Ganty J; Wajman A; Guedj D; Grosgogeat Y
Arch Mal Coeur Vaiss; 1983 Jan; 76(1):29-36. PubMed ID: 6303239
[TBL] [Abstract][Full Text] [Related]
42. Usefulness of orally active angiotensin I converting enzyme inhibitor (SQ 14,225) in the treatment of malignant hypertension.
Abe I; Kawasaki T; Ueno M; Kawano Y; Uezono K; Ogata M; Kawazoe N; Omae T; Fukiyama K
Fukuoka Igaku Zasshi; 1980 Mar; 71(3):157-66. PubMed ID: 6247259
[No Abstract] [Full Text] [Related]
43. Humoral and hemodynamic effects of increasing doses of captopril in patients with essential hypertension.
Sassano P; Pedrinelli R; Magagna A; Abdel-Haq B; Salvetti A
Am J Cardiol; 1982 Apr; 49(6):1574-6. PubMed ID: 6280486
[TBL] [Abstract][Full Text] [Related]
44. The exercise-induced rise in atrial natriuretic factor is reduced by chronic angiotensin converting enzyme inhibition in patients with primary hypertension.
Januszewicz A; Lapinski M; Stepniakowski K; Szczypaczewska M; Kowalik-Borowka E; Chlebus M; Kuch-Wocial A; Wocial B; Januszewicz W
J Hypertens Suppl; 1991 Dec; 9(6):S386-7. PubMed ID: 1840199
[No Abstract] [Full Text] [Related]
45. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
Campbell BC; Shepherd AN; Reid JL
Br J Clin Pharmacol; 1982 Feb; 13(2):213-7. PubMed ID: 6277356
[TBL] [Abstract][Full Text] [Related]
46. [Acute effects of angiotensin I converting enzyme inhibitor, captopril (SQ 14, 225) on severe heart failure--hemodynamics, plasma catecholamine levels, renin-angiotensin-aldosterone system and blood gas data (author's transl)].
Morimoto Y; Baba M; Takahashi T; Fujii M; Konishi T; Kawanami C; Hamada M; Nakano T; Takezawa H
Kokyu To Junkan; 1982 Mar; 30(3):317-25. PubMed ID: 6808624
[No Abstract] [Full Text] [Related]
47. [Antihypertensive, hemodynamic and endocrine effects of Captopril in arterial hypertension].
Valvo E; Previato G; Oldrizzi L; Corgnati A; Lupo A; Loschiavo C; Tessitore N; Maschio G
Minerva Nefrol; 1981; 28(2):139-41. PubMed ID: 7027091
[No Abstract] [Full Text] [Related]
48. Effects of captopril on the development of tolerance to guanethidine.
Rankin GO; Haas GJ
Fed Proc; 1984 Apr; 43(5):1342-5. PubMed ID: 6323227
[TBL] [Abstract][Full Text] [Related]
49. Long-term converting enzyme inhibition versus surgical treatment in hypertensive patients with renovascular disease.
Staessen J; Bulpitt CJ; Fagard R; Lijnen P; Amery A
Neth J Med; 1984; 27(4):161-4. PubMed ID: 6330590
[No Abstract] [Full Text] [Related]
50. Captopril - a genuine innovation.
Drug Ther Bull; 1982 Feb; 20(4):13-5. PubMed ID: 6277587
[No Abstract] [Full Text] [Related]
51. Evaluation of the chronotropic property of captopril in hypertensive patients.
Imai Y; Abe K; Sato M; Haruyama T; Hiwatari M; Goto T; Sato K; Kasai Y; Tajima J; Yoshinaga K
Am Heart J; 1982 Dec; 104(6):1339-45. PubMed ID: 6128916
[TBL] [Abstract][Full Text] [Related]
52. [Effect of captopril on arterial pressure, plasma renin activity and the autonomic nervous system in essential arterial hypertension with low-normal plasma renin activity].
Sturani A; Chiarini C; Degli Esposti E; Gattiani A; Masi A; Santoro A; Umile A; Zuccalà A; Zucchelli P
Minerva Nefrol; 1981; 28(3):265-9. PubMed ID: 7036015
[No Abstract] [Full Text] [Related]
53. [Renin-angiotensin system antagonists].
Ogawa M; Inagaki Y
Nihon Rinsho; 1983 Dec; 41(12):2703-8. PubMed ID: 6371300
[No Abstract] [Full Text] [Related]
54. [Captopril in severe arterial hypertension of childhood (authors transl)].
Bacri JL; Dechaux M; André JL; Gagnadoux MF; Broyer M
Arch Fr Pediatr; 1981 Dec; 38 Suppl 1():887-92. PubMed ID: 7036933
[TBL] [Abstract][Full Text] [Related]
55. [Successful treatment of severe refractory hypertension with captopril].
Gabizon D; Weissgarten Y; Pik A; Modai D
Harefuah; 1981 Oct; 101(7-8):167-9. PubMed ID: 6277749
[No Abstract] [Full Text] [Related]
56. Endocrine and cardiovascular influences of converting enzyme inhibition with SQ 14225 in hypertensive patients in the supine position and during head-up tilt before and after sodium depletion.
Morganti JA; Pickering TG; Lopez-Ovejero JA; Laragh JH
J Clin Endocrinol Metab; 1980 Apr; 50(4):748-54. PubMed ID: 6245101
[No Abstract] [Full Text] [Related]
57. [Evaluation of the acute effect of a converting enzyme inhibitor, captopril, in normal and hypertensive subjects].
Mimran A; Laroche B; Targhetta R; Roumieux JL
Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():61-5. PubMed ID: 6794529
[TBL] [Abstract][Full Text] [Related]
58. Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients.
Johns DW; Ayers CR; Williams SC
Hypertension; 1984; 6(4):545-50. PubMed ID: 6086518
[TBL] [Abstract][Full Text] [Related]
59. Influence of food on acute and chronic effects of captopril in essential hypertensive patients.
Salvetti A; Pedrinelli R; Magagna A; Abdel-Haq B; Graziadei L; Taddei S; Stornello M
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S25-9. PubMed ID: 2580172
[TBL] [Abstract][Full Text] [Related]
60. Acute effect of captopril on serum lipid peroxides level in hypertensive patients.
Mizuno K; Gotoh M; Fukuchi S
Tohoku J Exp Med; 1984 May; 143(1):127-8. PubMed ID: 6379987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
